









Markets
/
Stocks
/
nasdaq-atra
/

Atara Biotherapeutics Inc

ATRA

12.050USD

-0.020-0.17%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

84.08MMarket Cap

14.51P/E TTM



Atara Biotherapeutics Inc

12.050

-0.020-0.17%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

143 / 506

Overall Ranking

251 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

16.500

Target Price

+36.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 102.82% year-on-year.

Overvalued

The company’s latest PE is 16.12, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.91M shares, decreasing 25.68% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 190.76K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.58, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.57M, representing a year-over-year decrease of 38.63%, while its net profit experienced a year-over-year decrease of 112.53%.

Score

Industry at a Glance

Previous score

7.58

Change



Financials

6.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

3.95

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 16.15, which is -101.38% below the recent high of -0.22 and 187.94% above the recent low of -14.20.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 143/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.50, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Atara Biotherapeutics Inc is 16.50, with a high of 17.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

16.500

Target Price

+36.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Atara Biotherapeutics Inc

ATRA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.15, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 13.09 and the support level at 11.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.15

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.203

Neutral

RSI(14)

52.246

Neutral

STOCH(KDJ)(9,3,3)

45.638

Buy

ATR(14)

0.587

Low Volatility

CCI(14)

-30.329

Neutral

Williams %R

61.613

Sell

TRIX(12,20)

0.099

Sell

StochRSI(14)

96.271

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

11.832

Buy

MA10

11.935

Buy

MA20

12.200

Sell

MA50

11.603

Buy

MA100

9.761

Buy

MA200

9.343

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 73.40%, representing a quarter-over-quarter increase of 12.23%. The largest institutional shareholder is The Vanguard, holding a total of 190.76K shares, representing 2.72% of shares outstanding, with 10.99% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Panacea Venture

1.33M

+141.94%

Adiumentum Capital Fund I LP

1.28M

+13.33%

EcoR1 Capital, LLC

573.18K

+7.71%

Redmile Group, LLC

441.70K

The Vanguard Group, Inc.

Star Investors

190.76K

+6.70%

Vestal Point Capital, LP

94.08K

-24.73%

Staley Capital Advisers, Inc.

80.00K

+60.00%

BlackRock Institutional Trust Company, N.A.

56.01K

Acadian Asset Management LLC

115.11K

-7.52%

Geode Capital Management, L.L.C.

58.68K

+7.19%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.09, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.22. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.